Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk for Developing Complications

NCT02764762 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02764762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02764762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk for Developing Complications
Lead sponsor
Takeda
Phase
Phase 4
Overall status
Completed
Start date
April 18, 2017
Completion date
July 5, 2022
Enrollment
55 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease